Navigation Links
Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Date:11/2/2007

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

The FDA had previously reviewed Phase I through III clinical data involving gepirone ER. In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval as a new antidepressant treatment. Subsequently, FKP successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.

Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.

Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of gepirone extended-release tablets. Fabre-Kramer and GSK are evaluating the response from the FDA to determine appropriate next steps.

About Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas, is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
(Date:8/29/2014)... 29, 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... it intends to release its financial results for the ... 2014 after market trading ends on Tuesday, September 9, ... call for 4:30 p.m. U.S. EDT on Tuesday, September ... to review the Company,s financial results, commercial partnerships, and ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... Treatment. This is an absolutely unique method of curing ... The new program was created by Dr. Gary M. ... The health specialist started to become interested in alternative ... realized that classical remedies cannot be effective in all ...
(Date:8/29/2014)... 29, 2014 Dr. Mohebi’s lecture on ... talked about introducing these cutting edge techniques at their ... the FUE Research Committee has allowed him the ability ... is possible with modern technology. Dr. Mohebi stated, “We ... FUE devices that facilitate extraction and implantation of hair ...
(Date:8/29/2014)... reported by CNN.com in the article Prescription Drug Abuse: ... you need help for a prescription drug abuse problem can ... that if you simply try to find general help for ... the information that is available online. Although the information available ... possible to get help. The statistics from SAMSHA remind the ...
(Date:8/29/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Glass ... The report then explores global and China’s top ... capacity, Production value, and market share etc. , ...
(Date:8/29/2014)... Del Mar, CA (PRWEB) August 29, 2014 ... “oyasumi bra,” a bra developed by a Tokyo clothing store ... bed in the hopes of rectifying or diminishing their problem. ... has treated men with the problem. While many people only ... is actually a fairly common condition among men of all ...
Breaking Medicine News(10 mins):Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3
... in an extremely exciting phase right now. We are ... formed and are starting clinical trials in different areas," ... first-in-human study was just initiated for Parkinson,s disease patients ... NeuroNova. The drug, which is administered into the fluid-filled ...
... ST. PAUL, Minn., May 21 Three HealthEast ... agreed to pay the federal government a total ... tam") lawsuit alleging Medicare fraud involving a certain ... hospitals are the first hospitals to settle charges ...
... FRANCISCO -- Mayo Clinic researchers have found that bipolar ... as diabetes, depression, asthma or coronary artery disease. These ... claim costs. Specialty care costs (the costs of seeing ... for bipolar patients. Results of this review are being ...
... May 21 Elimination of funding for ... by the Senate Republican budget plan would end a ... rate of health care cost increases, improving quality of ... today.For the past two years the small "think tank" ...
... HMS today announced that it had been awarded contracts ... million lives to the company,s portfolio. HMS will be providing ... party recovery and cost avoidance -- to Citrus Health Care, ... (NY); Health First (NY); Health Plan of Michigan, Inc. (MI); ...
... (May 21, 2009) In comparing ultrasound with other medical ... review of published studies in the May/June issue of ... of ultrasound to provide an accurate diagnosis more cost ... the 1950s, ultrasound has been utilized mostly in hospital settings. ...
Cached Medicine News:Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: